Vigil's TREM2-Targeted Alzheimer's Treatment Shows Early Promise, Moves on to Phase II

Retrieved on: 2025-01-23 16:12:56

Tags for this article:

Click the tags to see associated articles and topics

Vigil's TREM2-Targeted Alzheimer's Treatment Shows Early Promise, Moves on to Phase II. View article details on hiswai:

Excerpt

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new ...

Article found on: www.biospace.com